solo per uso di ricerca
BMS-754807 IGF-1R inibitore
N. Cat.S1124
Struttura chimica
Peso molecolare: 461.49
Vai a
Controllo Qualità
Lotto:
Purezza:
99.72%
99.72
| Target correlati | EGFR VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 |
|---|---|
| Altro IGF-1R Inibitori | Linsitinib (OSI-906) BMS-536924 NVP-AEW541 Picropodophyllin (AXL1717) GSK1904529A AG-1024 NVP-ADW742 NT157 PQ 401 MSDC-0160 |
Coltura cellulare, trattamento e concentrazione di lavoro
| Linee cellulari | Tipo di saggio | Concentrazione | Tempo di incubazione | Formulazione | Descrizione dellattività | PMID |
|---|---|---|---|---|---|---|
| IGF-Sal | Kinase assay | inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) | 19778024 | |||
| IGF-Sal | Growth inhibitory assay | IC50=7 nM | 19778024 | |||
| CCRF-CEM (ALL) | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.239 μM | 19996272 | |
| PC3 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.965 μM | 19996272 | |
| JD | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.391 μM | 19996272 | |
| DU145 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.465 μM | 19996272 | |
| KAG | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.665 μM | 19996272 | |
| K-562 (CML) | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.302 μM | 19996272 | |
| B6-P210 (Murine ALL) | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.293 μM | 19996272 | |
| LN CAP-FGC | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.434 μM | 19996272 | |
| VW | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.019 μM | 19996272 | |
| MV411 (B Myelomonocytic) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.33 μM | 19996272 | |
| MDA-PCa-2b | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.098 μM | 19996272 | |
| LG | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.038 μM | 19996272 | |
| RS411 (B cell precursor-ALL) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.102 μM | 19996272 | |
| 22-r-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.175 μM | 19996272 | |
| 5838 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.034 μM | 19996272 | |
| P388 (Murine) | Growth inhibitory assay | ~5 μM | DMSO | IC50=4.27 μM | 19996272 | |
| A2780/S | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.122 μM | 19996272 | |
| RDES | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.012 μM | 19996272 | |
| B6-T315I (Murine B-ALL) | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.83 μM | 19996272 | |
| TOV 112D | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.146 μM | 19996272 | |
| TC32 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.008 μM | 19996272 | |
| HL60 (acute myelocytic) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.12 μM | 19996272 | |
| TOV 21G | Growth inhibitory assay | ~5 μM | DMSO | IC50=4.279 μM | 19996272 | |
| TC71 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.014 μM | 19996272 | |
| HPN-ALL (T-cell) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.52 μM | 19996272 | |
| A2780R | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.564 μM | 19996272 | |
| Rh1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.027 μM | 19996272 | |
| Kasumi-1 (acute myeloid) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.16 μM | 19996272 | |
| sk-ov-3 | Growth inhibitory assay | ~5 μM | DMSO | IC50=5.1 μM | 19996272 | |
| ME | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.015 μM | 19996272 | |
| L1210 (Murine lymphocytic) | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.39 μM | 19996272 | |
| sw-626 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.306 μM | 19996272 | |
| CTR | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.253 μM | 19996272 | |
| ML2 (Myelomonocytic) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.09 μM | 19996272 | |
| ovcar-3 | Growth inhibitory assay | ~5 μM | DMSO | IC50=5 μM | 19996272 | |
| Rh36 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.432 μM | 19996272 | |
| MOLM-13 (acute myeloid) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.42 μM | 19996272 | |
| ovcar-4 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1 μM | 19996272 | |
| Rh41 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.005 μM | 19996272 | |
| Mutz 2 (acute myeloid) | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.15 μM | 19996272 | |
| ovcar-5 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.05 μM | 19996272 | |
| RD1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.068 μM | 19996272 | |
| OCI-AML 2 (acute myeloid) | Growth inhibitory assay | ~5 μM | DMSO | IC50=3.33 μM | 19996272 | |
| 786-O | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.647 μM | 19996272 | |
| A673 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.408 μM | 19996272 | |
| TALL-1 (T-cell) | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.28 μM | 19996272 | |
| 151-B | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.67 μM | 19996272 | |
| PFSK-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.132 μM | 19996272 | |
| THP-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=6.58 μM | 19996272 | |
| HEK293 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.915 μM | 19996272 | |
| DAOY | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.979 μM | 19996272 | |
| SET2 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.298 μM | 19996272 | |
| HTB-46 | Growth inhibitory assay | ~5 μM | DMSO | IC50=5.25 μM | 19996272 | |
| SK-NAS | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.497 μM | 19996272 | |
| CTLL2 | Growth inhibitory assay | ~5 μM | DMSO | IC50>1.00 μM | 19996272 | |
| HTB-47 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.056 μM | 19996272 | |
| LAN-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.04 μM | 19996272 | |
| ST486 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.19 μM | 19996272 | |
| HS766T | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.001 μM | 19996272 | |
| IMR-32 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.261 μM | 19996272 | |
| Daudi (Burkitt's) | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.637 μM | 19996272 | |
| Aspc-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.379 μM | 19996272 | |
| SK-NSH | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.139 μM | 19996272 | |
| MEC-1 (Chronic B cell) | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.637 μM | 19996272 | |
| Capan-2 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.774 μM | 19996272 | |
| SHSY5Y | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.106 μM | 19996272 | |
| U937 (Histioocytic) | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| Bxpc-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.924 μM | 19996272 | |
| Bxpc-3 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| HTB-92 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.02 μM | 19996272 | |
| OCI-LY10 (B-cell) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.45 μM | 19996272 | |
| PANC-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| To184.T | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.469 μM | 19996272 | |
| OCI-LY19 (B-cell) | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.4 μM | 19996272 | |
| PANC-1 BM | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| SA-4 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.301 μM | 19996272 | |
| RPMI 8226 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.293 μM | 19996272 | |
| HPAF-II | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.644 μM | 19996272 | |
| SHP-77 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.888 μM | 19996272 | |
| U266 B1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.669 μM | 19996272 | |
| Hs700t | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.231 μM | 19996272 | |
| NCI-446 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.154 μM | 19996272 | |
| H929 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.014 μM | 19996272 | |
| PL45 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.255 μM | 19996272 | |
| NCI-H383 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| JJN3 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.433 μM | 19996272 | |
| SU.86.86 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.672 μM | 19996272 | |
| H1299 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| MDA-MB-468 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.504 μM | 19996272 | |
| SW1990 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.826 μM | 19996272 | |
| Calu-6 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| MDA-MB-231 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.648 μM | 19996272 | |
| SW-684 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| H209 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.193 μM | 19996272 | |
| MDA-MB-231T | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| HT1080/S | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.531 μM | 19996272 | |
| H526 0.044 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.044 μM | 19996272 | |
| DU4475 2.431 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.431 μM | 19996272 | |
| HCT116 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.852 μM | 19996272 | |
| M109 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.055 μM | 19996272 | |
| BT549 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.645 μM | 19996272 | |
| HCT116/VM46 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.702 μM | 19996272 | |
| H460 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.795 μM | 19996272 | |
| MCF-7 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.016 μM | 19996272 | |
| GEO | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.356 μM | 19996272 | |
| H441 0.646 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.646 μM | 19996272 | |
| MCF-7-807R | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.49 μM | 19996272 | |
| Colo205 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.104 μM | 19996272 | |
| H292 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.788 μM | 19996272 | |
| BT474 (S) | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.403 μM | 19996272 | |
| HT-29 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.103 μM | 19996272 | |
| A549 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.675 μM | 19996272 | |
| BT474-M1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.365 μM | 19996272 | |
| SW480 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| L2987 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.442 μM | 19996272 | |
| AU565 | Growth inhibitory assay | ~5 μM | DMSO | IC50=4.97 μM | 19996272 | |
| SW403 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.22 μM | 19996272 | |
| H1437 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.523 μM | 19996272 | |
| BT-20 | Growth inhibitory assay | ~5 μM | DMSO | IC50=3.562 μM | 19996272 | |
| Colo320HSR | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.011 μM | 19996272 | |
| H2087 | Growth inhibitory assay | ~5 μM | DMSO | IC50>1.00 μM | 19996272 | |
| HCC1419 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.517 μM | 19996272 | |
| WiDr | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.076 μM | 19996272 | |
| H661 0.573 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.573 μM | 19996272 | |
| HCC-38 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| LS174T | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.535 μM | 19996272 | |
| H211 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.733 μM | 19996272 | |
| HCC70 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.55 μM | 19996272 | |
| SW116 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.067 μM | 19996272 | |
| H513 | Growth inhibitory assay | ~5 μM | DMSO | IC50=4.448 μM | 19996272 | |
| MDA-MB-157 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.036 μM | 19996272 | |
| H2052 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.05 μM | 19996272 | |
| MDA-MB-415 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| DLD-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.909 μM | 19996272 | |
| H2595 | Growth inhibitory assay | ~5 μM | DMSO | IC50=4.475 μM | 19996272 | |
| MDA-MB-435S | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.869 μM | 19996272 | |
| HCT15 | Growth inhibitory assay | ~5 μM | DMSO | IC50>1.00 μM | 19996272 | |
| SK-Hep1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.146 μM | 19996272 | |
| MDA-MB-436 | Growth inhibitory assay | ~5 μM | DMSO | IC50=5.502 μM | 19996272 | |
| KM12C | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.054 μM | 19996272 | |
| HEPG2 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.025 μM | 19996272 | |
| MDA-MB-453 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.869 μM | 19996272 | |
| KM12SM | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.059 μM | 19996272 | |
| 1483 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.19 μM | 19996272 | |
| Hs578t | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.287 μM | 19996272 | |
| LS180 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.696 μM | 19996272 | |
| FaDu | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.27 μM | 19996272 | |
| ZR-75-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2.084 μM | 19996272 | |
| LS513 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.135 μM | 19996272 | |
| Detroit.562 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.14 μM | 19996272 | |
| ZR-75-30 | Growth inhibitory assay | ~5 μM | DMSO | IC50>5.00 μM | 19996272 | |
| RKO-PM | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.232 μM | 19996272 | |
| Cal.27 | Growth inhibitory assay | ~5 μM | DMSO | IC50=2 μM | 19996272 | |
| KPL4 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.252 μM | 19996272 | |
| PKO-RM13 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.425 μM | 19996272 | |
| HS.53.T | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.79 μM | 19996272 | |
| EMT6 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.806 μM | 19996272 | |
| SNU-C1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.007 μM | 19996272 | |
| SQCCY1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.79 μM | 19996272 | |
| SW480 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.037 μM | 19996272 | |
| SCC9 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.75 μM | 19996272 | |
| SK-LMS-1 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.687 μM | 19996272 | |
| SCC25 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.68 μM | 19996272 | |
| U87 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.95 μM | 19996272 | |
| SCC15 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.67 μM | 19996272 | |
| T98G | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.218 μM | 19996272 | |
| SCC4 | Growth inhibitory assay | ~5 μM | DMSO | IC50=0.63 μM | 19996272 | |
| U118 | Growth inhibitory assay | ~5 μM | DMSO | IC50=1.618 μM | 19996272 | |
| TU167 | Growth inhibitory assay | ~5 μM | DMSO | IC50=4.52 μM | 19996272 | |
| NCI-H727 | Growth inhibitory assay | ~10 μM | DMSO | IC50=428 nM | 20385747 | |
| NCI-H720 | Growth inhibitory assay | ~10 μM | DMSO | IC50=2.8 μM | 20385747 | |
| NCI-H835 | Growth inhibitory assay | ~10 μM | DMSO | IC50=1 μM | 20385747 | |
| NCI-H727 | Kinase assay | ~10 μM | DMSO | inhibits constitutive IGF1R autophosphorylation | 20385747 | |
| RD | Growth inhibitory assay | ~10 μM | IC50=1.12 µM | 21298745 | ||
| Rh41 | Growth inhibitory assay | ~10 μM | IC50=0.07 µM | 21298745 | ||
| Rh18 | Growth inhibitory assay | ~10 μM | IC50=4.96 µM | 21298745 | ||
| Rh30 | Growth inhibitory assay | ~10 μM | IC50=0.19 µM | 21298745 | ||
| BT-12 | Growth inhibitory assay | ~10 μM | IC50=0.78 µM | 21298745 | ||
| CHLA-266 | Growth inhibitory assay | ~10 μM | IC50=0.89 µM | 21298745 | ||
| TC-71 | Growth inhibitory assay | ~10 μM | IC50=0.11 µM | 21298745 | ||
| CHLA-9 | Growth inhibitory assay | ~10 μM | IC50=0.12 µM | 21298745 | ||
| CHLA-10 | Growth inhibitory assay | ~10 μM | IC50=0.62 µM | 21298745 | ||
| CHLA-258 | Growth inhibitory assay | ~10 μM | IC50=0.27 µM | 21298745 | ||
| GBM2 | Growth inhibitory assay | ~10 μM | IC50=1.47 µM | 21298745 | ||
| NB-1643 | Growth inhibitory assay | ~10 μM | IC50=0.12 µM | 21298745 | ||
| NB-EBc1 | Growth inhibitory assay | ~10 μM | IC50=0.35 µM | 21298745 | ||
| CHLA-90 | Growth inhibitory assay | ~10 μM | IC50=0.77 µM | 21298745 | ||
| CHLA-136 | Growth inhibitory assay | ~10 μM | IC50=0.52 µM | 21298745 | ||
| NALM-6 | Growth inhibitory assay | ~10 μM | IC50=0.49 µM | 21298745 | ||
| COG-LL-317 | Growth inhibitory assay | ~10 μM | IC50=1.38 µM | 21298745 | ||
| RS4;11 | Growth inhibitory assay | ~10 μM | IC50=0.38 µM | 21298745 | ||
| MOLT-4 | Growth inhibitory assay | ~10 μM | IC50=0.53 µM | 21298745 | ||
| CCRF-CEM | Growth inhibitory assay | ~10 μM | IC50=1.13 µM | 21298745 | ||
| Kasumi-1 | Growth inhibitory assay | ~10 μM | IC50=1.2 µM | 21298745 | ||
| Karpas-299 | Growth inhibitory assay | ~10 μM | IC50=1.64 µM | 21298745 | ||
| Ramos-RA1 | Growth inhibitory assay | ~10 μM | IC50=1.31 µM | 21298745 | ||
| Rh30 | Function assay | induces an increase of SFK phosphorylation | 25925378 | |||
| Rh41 | Function assay | induces an increase of SFK phosphorylation | 25925378 | |||
| RD | Function assay | induces an increase of SFK phosphorylation | 25925378 | |||
| A549 | Kinase assay | 0.5 μM | DMSO | inhibits IGF-IR/IR activation | 26928578 | |
| NCI-H358 | Kinase assay | 0.5 μM | DMSO | inhibits IGF-IR/IR activation | 26928578 | |
| A549 | Function assay | 0.5 μM | DMSO | causes a concurrent decrease in phosphorylated AKT and ERK | 26928578 | |
| NCI-H358 | Function assay | 0.5 μM | DMSO | causes a concurrent decrease in phosphorylated AKT and ERK | 26928578 | |
| A549 | Growth inhibitory assay | ~10 μM | DMSO | IC50=0.76 μM | 26928578 | |
| NCI-H358 | Growth inhibitory assay | ~10 μM | DMSO | IC50=1.09 μM | 26928578 | |
| A549 | Apoptosis assay | 0.5 μM | DMSO | induces Apoptosis | 26928578 | |
| NCI-H358 | Apoptosis assay | 0.5 μM | DMSO | induces Apoptosis | 26928578 | |
| A549 | Function assay | 0.5 μM | DMSO | reduces wound closure | 26928578 | |
| NCI-H358 | Function assay | 0.5 μM | DMSO | reduces wound closure | 26928578 | |
| IGF1R-SAL | Function assay | Inhibition of IGF1R in IGF1R-SAL cells, IC50 = 0.0021 μM. | 20675137 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| wild type fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | |||
| wild type fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 29435139 | |||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | |||
| COLO-205 | Growth Inhibition Assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50 = 0.002243 μM. | SANGER | |||
| EW-1 | Growth Inhibition Assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 0.003998 μM. | SANGER | |||
| TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 0.004197 μM. | SANGER | |||
| A4-Fuk | Growth Inhibition Assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 0.0057 μM. | SANGER | |||
| PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 0.008604 μM. | SANGER | |||
| Saos-2 | Growth Inhibition Assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 0.00962 μM. | SANGER | |||
| HT-29 | Growth Inhibition Assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 0.01226 μM. | SANGER | |||
| NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 0.01401 μM. | SANGER | |||
| NCI-H2122 | Growth Inhibition Assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 0.01458 μM. | SANGER | |||
| ES1 | Growth Inhibition Assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 0.01594 μM. | SANGER | |||
| KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 0.01594 μM. | SANGER | |||
| EW-16 | Growth Inhibition Assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 0.02095 μM. | SANGER | |||
| LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 0.02296 μM. | SANGER | |||
| NCI-H650 | Growth Inhibition Assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 0.02652 μM. | SANGER | |||
| NCI-H727 | Growth Inhibition Assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 0.03011 μM. | SANGER | |||
| NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 0.03084 μM. | SANGER | |||
| T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 0.03359 μM. | SANGER | |||
| SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 0.03578 μM. | SANGER | |||
| TE-8 | Growth Inhibition Assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 0.03654 μM. | SANGER | |||
| ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.03695 μM. | SANGER | |||
| HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 0.03791 μM. | SANGER | |||
| LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 0.04354 μM. | SANGER | |||
| LS-1034 | Growth Inhibition Assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 0.04606 μM. | SANGER | |||
| BFTC-905 | Growth Inhibition Assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 0.04727 μM. | SANGER | |||
| SIG-M5 | Growth Inhibition Assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50 = 0.04819 μM. | SANGER | |||
| GDM-1 | Growth Inhibition Assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50 = 0.05338 μM. | SANGER | |||
| GP5d | Growth Inhibition Assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 0.05404 μM. | SANGER | |||
| NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 0.05571 μM. | SANGER | |||
| EW-11 | Growth Inhibition Assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 0.0558 μM. | SANGER | |||
| KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.05722 μM. | SANGER | |||
| EW-7 | Growth Inhibition Assay | Inhibition of human EW-7 cell growth in a cell viability assay, IC50 = 0.06101 μM. | SANGER | |||
| A375 | Growth Inhibition Assay | Inhibition of human A375 cell growth in a cell viability assay, IC50 = 0.06678 μM. | SANGER | |||
| G-401 | Growth Inhibition Assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 0.06781 μM. | SANGER | |||
| IGROV-1 | Growth Inhibition Assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 0.06857 μM. | SANGER | |||
| MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 0.07149 μM. | SANGER | |||
| MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 0.07154 μM. | SANGER | |||
| EW-18 | Growth Inhibition Assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.07157 μM. | SANGER | |||
| HCC2998 | Growth Inhibition Assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 0.0719 μM. | SANGER | |||
| ES4 | Growth Inhibition Assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 0.07293 μM. | SANGER | |||
| SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 0.07792 μM. | SANGER | |||
| PSN1 | Growth Inhibition Assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50 = 0.07822 μM. | SANGER | |||
| CAL-39 | Growth Inhibition Assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 0.08259 μM. | SANGER | |||
| SNU-C1 | Growth Inhibition Assay | Inhibition of human SNU-C1 cell growth in a cell viability assay, IC50 = 0.08617 μM. | SANGER | |||
| CMK | Growth Inhibition Assay | Inhibition of human CMK cell growth in a cell viability assay, IC50 = 0.09283 μM. | SANGER | |||
| MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 0.09299 μM. | SANGER | |||
| ES8 | Growth Inhibition Assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 0.10016 μM. | SANGER | |||
| RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.1024 μM. | SANGER | |||
| NCI-H1437 | Growth Inhibition Assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 0.10534 μM. | SANGER | |||
| SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 0.10982 μM. | SANGER | |||
| GCIY | Growth Inhibition Assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 0.11182 μM. | SANGER | |||
| ABC-1 | Growth Inhibition Assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 0.11695 μM. | SANGER | |||
| MHH-ES-1 | Growth Inhibition Assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 0.12206 μM. | SANGER | |||
| NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 0.12427 μM. | SANGER | |||
| COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 0.13232 μM. | SANGER | |||
| NCI-H810 | Growth Inhibition Assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 0.13707 μM. | SANGER | |||
| CHP-212 | Growth Inhibition Assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 0.15162 μM. | SANGER | |||
| LB647-SCLC | Growth Inhibition Assay | Inhibition of human LB647-SCLC cell growth in a cell viability assay, IC50 = 0.1549 μM. | SANGER | |||
| NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 0.16075 μM. | SANGER | |||
| RH-1 | Growth Inhibition Assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 0.16629 μM. | SANGER | |||
| CAL-85-1 | Growth Inhibition Assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 0.16738 μM. | SANGER | |||
| NB10 | Growth Inhibition Assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 0.17084 μM. | SANGER | |||
| RPMI-2650 | Growth Inhibition Assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 0.17567 μM. | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 0.17778 μM. | SANGER | |||
| NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 0.17943 μM. | SANGER | |||
| COLO-320-HSR | Growth Inhibition Assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 0.17958 μM. | SANGER | |||
| MC-IXC | Growth Inhibition Assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 0.17996 μM. | SANGER | |||
| HMV-II | Growth Inhibition Assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50 = 0.18325 μM. | SANGER | |||
| LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 0.18349 μM. | SANGER | |||
| RD | Growth Inhibition Assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 0.18531 μM. | SANGER | |||
| DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 0.19484 μM. | SANGER | |||
| SK-CO-1 | Growth Inhibition Assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50 = 0.19724 μM. | SANGER | |||
| LAN-6 | Growth Inhibition Assay | Inhibition of human LAN-6 cell growth in a cell viability assay, IC50 = 0.19876 μM. | SANGER | |||
| NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 0.19905 μM. | SANGER | |||
| Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 0.20635 μM. | SANGER | |||
| NMC-G1 | Growth Inhibition Assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 0.20852 μM. | SANGER | |||
| ES6 | Growth Inhibition Assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 0.21402 μM. | SANGER | |||
| MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 0.21584 μM. | SANGER | |||
| SW1710 | Growth Inhibition Assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 0.216 μM. | SANGER | |||
| PANC-10-05 | Growth Inhibition Assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 0.21713 μM. | SANGER | |||
| ES3 | Growth Inhibition Assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 0.22285 μM. | SANGER | |||
| SK-PN-DW | Growth Inhibition Assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 0.22786 μM. | SANGER | |||
| SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 0.22835 μM. | SANGER | |||
| A427 | Growth Inhibition Assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 0.24322 μM. | SANGER | |||
| SK-LU-1 | Growth Inhibition Assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 0.2433 μM. | SANGER | |||
| MIA-PaCa-2 | Growth Inhibition Assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 0.25262 μM. | SANGER | |||
| SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 0.25834 μM. | SANGER | |||
| LC-2-ad | Growth Inhibition Assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 0.27037 μM. | SANGER | |||
| MG-63 | Growth Inhibition Assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 0.27622 μM. | SANGER | |||
| HUTU-80 | Growth Inhibition Assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50 = 0.27884 μM. | SANGER | |||
| HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 0.28448 μM. | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 0.3261 μM. | SANGER | |||
| SIMA | Growth Inhibition Assay | Inhibition of human SIMA cell growth in a cell viability assay, IC50 = 0.34069 μM. | SANGER | |||
| LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 0.34124 μM. | SANGER | |||
| EKVX | Growth Inhibition Assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 0.35075 μM. | SANGER | |||
| NCI-H441 | Growth Inhibition Assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 0.35395 μM. | SANGER | |||
| A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 0.35421 μM. | SANGER | |||
| HCC2157 | Growth Inhibition Assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 0.35686 μM. | SANGER | |||
| TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 0.35705 μM. | SANGER | |||
| TE-12 | Growth Inhibition Assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 0.35841 μM. | SANGER | |||
| GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 0.3628 μM. | SANGER | |||
| NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.36369 μM. | SANGER | |||
| NCI-H292 | Growth Inhibition Assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 0.36962 μM. | SANGER | |||
| CAL-12T | Growth Inhibition Assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 0.37216 μM. | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 0.37933 μM. | SANGER | |||
| L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 0.38703 μM. | SANGER | |||
| SK-MM-2 | Growth Inhibition Assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50 = 0.39516 μM. | SANGER | |||
| CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 0.40269 μM. | SANGER | |||
| NCI-H2171 | Growth Inhibition Assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50 = 0.41171 μM. | SANGER | |||
| SK-MEL-2 | Growth Inhibition Assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 0.41805 μM. | SANGER | |||
| COLO-668 | Growth Inhibition Assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 0.42737 μM. | SANGER | |||
| TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 0.43088 μM. | SANGER | |||
| CHP-126 | Growth Inhibition Assay | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50 = 0.43102 μM. | SANGER | |||
| LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 0.44655 μM. | SANGER | |||
| SBC-5 | Growth Inhibition Assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 0.47041 μM. | SANGER | |||
| BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 0.47733 μM. | SANGER | |||
| SW982 | Growth Inhibition Assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 0.47869 μM. | SANGER | |||
| OVCAR-5 | Growth Inhibition Assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 0.50207 μM. | SANGER | |||
| CCF-STTG1 | Growth Inhibition Assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50 = 0.51374 μM. | SANGER | |||
| KYSE-510 | Growth Inhibition Assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 0.51755 μM. | SANGER | |||
| TE-1 | Growth Inhibition Assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 0.54963 μM. | SANGER | |||
| CPC-N | Growth Inhibition Assay | Inhibition of human CPC-N cell growth in a cell viability assay, IC50 = 0.55598 μM. | SANGER | |||
| KGN | Growth Inhibition Assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 0.55892 μM. | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50 = 0.56224 μM. | SANGER | |||
| TE-441-T | Growth Inhibition Assay | Inhibition of human TE-441-T cell growth in a cell viability assay, IC50 = 0.56355 μM. | SANGER | |||
| BC-1 | Growth Inhibition Assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50 = 0.58745 μM. | SANGER | |||
| 5637 | Growth Inhibition Assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 0.60092 μM. | SANGER | |||
| A673 | Growth Inhibition Assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 0.60486 μM. | SANGER | |||
| OPM-2 | Growth Inhibition Assay | Inhibition of human OPM-2 cell growth in a cell viability assay, IC50 = 0.61161 μM. | SANGER | |||
| DK-MG | Growth Inhibition Assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 0.61751 μM. | SANGER | |||
| HGC-27 | Growth Inhibition Assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 0.62379 μM. | SANGER | |||
| TE-10 | Growth Inhibition Assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 0.63065 μM. | SANGER | |||
| VA-ES-BJ | Growth Inhibition Assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 0.63247 μM. | SANGER | |||
| KOSC-2 | Growth Inhibition Assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 0.63721 μM. | SANGER | |||
| LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 0.64357 μM. | SANGER | |||
| NCI-H1299 | Growth Inhibition Assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 0.64814 μM. | SANGER | |||
| AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 0.65646 μM. | SANGER | |||
| MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 0.65987 μM. | SANGER | |||
| BB30-HNC | Growth Inhibition Assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 0.66381 μM. | SANGER | |||
| HSC-3 | Growth Inhibition Assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 0.66843 μM. | SANGER | |||
| SNB75 | Growth Inhibition Assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 0.67377 μM. | SANGER | |||
| NCI-H1770 | Growth Inhibition Assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 0.67403 μM. | SANGER | |||
| SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 0.6926 μM. | SANGER | |||
| NCI-H2141 | Growth Inhibition Assay | Inhibition of human NCI-H2141 cell growth in a cell viability assay, IC50 = 0.69819 μM. | SANGER | |||
| SK-OV-3 | Growth Inhibition Assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 0.71264 μM. | SANGER | |||
| GI-1 | Growth Inhibition Assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 0.72502 μM. | SANGER | |||
| NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 0.72829 μM. | SANGER | |||
| NB1 | Growth Inhibition Assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50 = 0.73121 μM. | SANGER | |||
| NCI-H1618 | Growth Inhibition Assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50 = 0.73903 μM. | SANGER | |||
| DMS-273 | Growth Inhibition Assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 0.74175 μM. | SANGER | |||
| SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 0.74963 μM. | SANGER | |||
| RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 0.75108 μM. | SANGER | |||
| NCI-H1734 | Growth Inhibition Assay | Inhibition of human NCI-H1734 cell growth in a cell viability assay, IC50 = 0.7629 μM. | SANGER | |||
| SNG-M | Growth Inhibition Assay | Inhibition of human SNG-M cell growth in a cell viability assay, IC50 = 0.78394 μM. | SANGER | |||
| LS-513 | Growth Inhibition Assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 0.78587 μM. | SANGER | |||
| SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 0.78676 μM. | SANGER | |||
| LCLC-103H | Growth Inhibition Assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 0.78834 μM. | SANGER | |||
| SW954 | Growth Inhibition Assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 0.79303 μM. | SANGER | |||
| COLO-680N | Growth Inhibition Assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 0.79945 μM. | SANGER | |||
| NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 0.80182 μM. | SANGER | |||
| SW620 | Growth Inhibition Assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 0.80713 μM. | SANGER | |||
| KYSE-270 | Growth Inhibition Assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 0.80989 μM. | SANGER | |||
| NCI-H1882 | Growth Inhibition Assay | Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50 = 0.81014 μM. | SANGER | |||
| YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 0.83103 μM. | SANGER | |||
| A2780 | Growth Inhibition Assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 0.86327 μM. | SANGER | |||
| MES-SA | Growth Inhibition Assay | Inhibition of human MES-SA cell growth in a cell viability assay, IC50 = 0.87372 μM. | SANGER | |||
| BCPAP | Growth Inhibition Assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 0.87737 μM. | SANGER | |||
| H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 0.90356 μM. | SANGER | |||
| EW-13 | Growth Inhibition Assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 0.909 μM. | SANGER | |||
| HSC-2 | Growth Inhibition Assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 0.91076 μM. | SANGER | |||
| TE-15 | Growth Inhibition Assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50 = 0.95556 μM. | SANGER | |||
| COR-L23 | Growth Inhibition Assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 0.9653 μM. | SANGER | |||
| 786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 0.96904 μM. | SANGER | |||
| A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 0.97646 μM. | SANGER | |||
| G-402 | Growth Inhibition Assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 0.97855 μM. | SANGER | |||
| 639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 0.99007 μM. | SANGER | |||
| SW872 | Growth Inhibition Assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 0.99324 μM. | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 0.99816 μM. | SANGER | |||
| HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 1.01305 μM. | SANGER | |||
| NCI-H1304 | Growth Inhibition Assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 1.02172 μM. | SANGER | |||
| GAMG | Growth Inhibition Assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 1.02372 μM. | SANGER | |||
| G-361 | Growth Inhibition Assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 1.03515 μM. | SANGER | |||
| LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 1.04553 μM. | SANGER | |||
| IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 1.06361 μM. | SANGER | |||
| SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 1.08487 μM. | SANGER | |||
| KINGS-1 | Growth Inhibition Assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 1.08504 μM. | SANGER | |||
| DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 1.10005 μM. | SANGER | |||
| NB5 | Growth Inhibition Assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 1.11259 μM. | SANGER | |||
| HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 1.117 μM. | SANGER | |||
| MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 1.13564 μM. | SANGER | |||
| CAKI-1 | Growth Inhibition Assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 1.14346 μM. | SANGER | |||
| ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 1.14642 μM. | SANGER | |||
| NCI-H1792 | Growth Inhibition Assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 1.15225 μM. | SANGER | |||
| NCI-H522 | Growth Inhibition Assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50 = 1.16468 μM. | SANGER | |||
| HOP-62 | Growth Inhibition Assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50 = 1.16571 μM. | SANGER | |||
| AGS | Growth Inhibition Assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 1.16817 μM. | SANGER | |||
| SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 1.16879 μM. | SANGER | |||
| COLO-679 | Growth Inhibition Assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 1.16945 μM. | SANGER | |||
| PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 1.17005 μM. | SANGER | |||
| Detroit562 | Growth Inhibition Assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 1.1769 μM. | SANGER | |||
| SK-N-FI | Growth Inhibition Assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 1.18752 μM. | SANGER | |||
| SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 1.19561 μM. | SANGER | |||
| Daoy | Growth Inhibition Assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 1.20848 μM. | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 1.22299 μM. | SANGER | |||
| 8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 1.23744 μM. | SANGER | |||
| RKO | Growth Inhibition Assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 1.24389 μM. | SANGER | |||
| DBTRG-05MG | Growth Inhibition Assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 1.26195 μM. | SANGER | |||
| HOS | Growth Inhibition Assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 1.27425 μM. | SANGER | |||
| D-542MG | Growth Inhibition Assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 1.27994 μM. | SANGER | |||
| ST486 | Growth Inhibition Assay | Inhibition of human ST486 cell growth in a cell viability assay, IC50 = 1.28117 μM. | SANGER | |||
| NY | Growth Inhibition Assay | Inhibition of human NY cell growth in a cell viability assay, IC50 = 1.28965 μM. | SANGER | |||
| NCI-H838 | Growth Inhibition Assay | Inhibition of human NCI-H838 cell growth in a cell viability assay, IC50 = 1.2914 μM. | SANGER | |||
| BB65-RCC | Growth Inhibition Assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 1.3022 μM. | SANGER | |||
| MEL-HO | Growth Inhibition Assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 1.31336 μM. | SANGER | |||
| HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 1.31847 μM. | SANGER | |||
| CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 1.32561 μM. | SANGER | |||
| SK-UT-1 | Growth Inhibition Assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 1.32799 μM. | SANGER | |||
| KALS-1 | Growth Inhibition Assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 1.32907 μM. | SANGER | |||
| LB831-BLC | Growth Inhibition Assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 1.34639 μM. | SANGER | |||
| KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 1.35266 μM. | SANGER | |||
| 8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 1.35994 μM. | SANGER | |||
| BHY | Growth Inhibition Assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 1.37413 μM. | SANGER | |||
| ONS-76 | Growth Inhibition Assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 1.37892 μM. | SANGER | |||
| BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 1.38403 μM. | SANGER | |||
| SK-HEP-1 | Growth Inhibition Assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 1.39441 μM. | SANGER | |||
| SK-LMS-1 | Growth Inhibition Assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 1.3969 μM. | SANGER | |||
| SNU-423 | Growth Inhibition Assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 1.41951 μM. | SANGER | |||
| SF295 | Growth Inhibition Assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 1.43606 μM. | SANGER | |||
| J82 | Growth Inhibition Assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 1.43959 μM. | SANGER | |||
| SW837 | Growth Inhibition Assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 1.46365 μM. | SANGER | |||
| TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 1.47786 μM. | SANGER | |||
| LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 1.51747 μM. | SANGER | |||
| NKM-1 | Growth Inhibition Assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 1.52468 μM. | SANGER | |||
| A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 1.52721 μM. | SANGER | |||
| A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 1.52944 μM. | SANGER | |||
| TK10 | Growth Inhibition Assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 1.52958 μM. | SANGER | |||
| MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 1.54338 μM. | SANGER | |||
| SF126 | Growth Inhibition Assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 1.55086 μM. | SANGER | |||
| OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 1.55193 μM. | SANGER | |||
| OCUB-M | Growth Inhibition Assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 1.55373 μM. | SANGER | |||
| K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 1.58531 μM. | SANGER | |||
| OE33 | Growth Inhibition Assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 1.59842 μM. | SANGER | |||
| EFO-21 | Growth Inhibition Assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 1.60098 μM. | SANGER | |||
| NB13 | Growth Inhibition Assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 1.62119 μM. | SANGER | |||
| SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 1.62851 μM. | SANGER | |||
| ETK-1 | Growth Inhibition Assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 1.6299 μM. | SANGER | |||
| SW1573 | Growth Inhibition Assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 1.64332 μM. | SANGER | |||
| NCI-H2170 | Growth Inhibition Assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 1.64499 μM. | SANGER | |||
| NCI-H1417 | Growth Inhibition Assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50 = 1.67323 μM. | SANGER | |||
| HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 1.68209 μM. | SANGER | |||
| NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 1.69318 μM. | SANGER | |||
| CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 1.69608 μM. | SANGER | |||
| LS-123 | Growth Inhibition Assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 1.69741 μM. | SANGER | |||
| SCC-15 | Growth Inhibition Assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 1.70193 μM. | SANGER | |||
| HuP-T4 | Growth Inhibition Assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 1.72836 μM. | SANGER | |||
| HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 1.76211 μM. | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 1.76781 μM. | SANGER | |||
| A204 | Growth Inhibition Assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 1.77017 μM. | SANGER | |||
| NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 1.77157 μM. | SANGER | |||
| NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 1.7974 μM. | SANGER | |||
| SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 1.80324 μM. | SANGER | |||
| GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 1.80864 μM. | SANGER | |||
| OAW-42 | Growth Inhibition Assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 1.85365 μM. | SANGER | |||
| KYSE-410 | Growth Inhibition Assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 1.85455 μM. | SANGER | |||
| NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 1.85475 μM. | SANGER | |||
| 22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 1.85754 μM. | SANGER | |||
| Becker | Growth Inhibition Assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 1.86663 μM. | SANGER | |||
| OE19 | Growth Inhibition Assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50 = 1.87707 μM. | SANGER | |||
| ACHN | Growth Inhibition Assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 1.87709 μM. | SANGER | |||
| RXF393 | Growth Inhibition Assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 1.87802 μM. | SANGER | |||
| NCI-H187 | Growth Inhibition Assay | Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50 = 1.89063 μM. | SANGER | |||
| PC-3 | Growth Inhibition Assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 1.92634 μM. | SANGER | |||
| DU-145 | Growth Inhibition Assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50 = 1.92988 μM. | SANGER | |||
| ESS-1 | Growth Inhibition Assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 1.9306 μM. | SANGER | |||
| NCI-H716 | Growth Inhibition Assay | Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50 = 1.94349 μM. | SANGER | |||
| SUP-T1 | Growth Inhibition Assay | Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50 = 1.96941 μM. | SANGER | |||
| SNU-449 | Growth Inhibition Assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 1.99372 μM. | SANGER | |||
| BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 2.00569 μM. | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 2.01324 μM. | SANGER | |||
| MDA-MB-468 | Growth Inhibition Assay | Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50 = 2.01868 μM. | SANGER | |||
| 8-MG-BA | Growth Inhibition Assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 2.01969 μM. | SANGER | |||
| NCI-H2052 | Growth Inhibition Assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 2.04159 μM. | SANGER | |||
| CAL-120 | Growth Inhibition Assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 2.05591 μM. | SANGER | |||
| M059J | Growth Inhibition Assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 2.06014 μM. | SANGER | |||
| U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 2.06897 μM. | SANGER | |||
| MFE-296 | Growth Inhibition Assay | Inhibition of human MFE-296 cell growth in a cell viability assay, IC50 = 2.07128 μM. | SANGER | |||
| SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 2.08184 μM. | SANGER | |||
| SCLC-21H | Growth Inhibition Assay | Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50 = 2.0999 μM. | SANGER | |||
| A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 2.10206 μM. | SANGER | |||
| KYSE-140 | Growth Inhibition Assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 2.11619 μM. | SANGER | |||
| MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 2.11642 μM. | SANGER | |||
| SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 2.12309 μM. | SANGER | |||
| MONO-MAC-6 | Growth Inhibition Assay | Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50 = 2.13231 μM. | SANGER | |||
| KYSE-450 | Growth Inhibition Assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 2.13843 μM. | SANGER | |||
| NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 2.14893 μM. | SANGER | |||
| LU-65 | Growth Inhibition Assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 2.15051 μM. | SANGER | |||
| MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 2.1569 μM. | SANGER | |||
| KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 2.16631 μM. | SANGER | |||
| NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 2.16852 μM. | SANGER | |||
| ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 2.18649 μM. | SANGER | |||
| CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 2.22588 μM. | SANGER | |||
| KYSE-150 | Growth Inhibition Assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 2.25119 μM. | SANGER | |||
| T-24 | Growth Inhibition Assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 2.25544 μM. | SANGER | |||
| AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 2.27715 μM. | SANGER | |||
| NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 2.30326 μM. | SANGER | |||
| SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 2.3107 μM. | SANGER | |||
| EFE-184 | Growth Inhibition Assay | Inhibition of human EFE-184 cell growth in a cell viability assay, IC50 = 2.3336 μM. | SANGER | |||
| A704 | Growth Inhibition Assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 2.345 μM. | SANGER | |||
| COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 2.35695 μM. | SANGER | |||
| DMS-153 | Growth Inhibition Assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50 = 2.38808 μM. | SANGER | |||
| TGW | Growth Inhibition Assay | Inhibition of human TGW cell growth in a cell viability assay, IC50 = 2.40252 μM. | SANGER | |||
| U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 2.41075 μM. | SANGER | |||
| ACN | Growth Inhibition Assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 2.45048 μM. | SANGER | |||
| KP-N-YN | Growth Inhibition Assay | Inhibition of human KP-N-YN cell growth in a cell viability assay, IC50 = 2.46004 μM. | SANGER | |||
| EGI-1 | Growth Inhibition Assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 2.49591 μM. | SANGER | |||
| UMC-11 | Growth Inhibition Assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50 = 2.51219 μM. | SANGER | |||
| SK-N-AS | Growth Inhibition Assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 2.54232 μM. | SANGER | |||
| SF268 | Growth Inhibition Assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 2.55044 μM. | SANGER | |||
| KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 2.56467 μM. | SANGER | |||
| VMRC-RCZ | Growth Inhibition Assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 2.57247 μM. | SANGER | |||
| NCCIT | Growth Inhibition Assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50 = 2.60543 μM. | SANGER | |||
| HOP-92 | Growth Inhibition Assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 2.61037 μM. | SANGER | |||
| MDA-MB-231 | Growth Inhibition Assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 2.61419 μM. | SANGER | |||
| NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 2.62328 μM. | SANGER | |||
| CAL-62 | Growth Inhibition Assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 2.66243 μM. | SANGER | |||
| HO-1-N-1 | Growth Inhibition Assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 2.66336 μM. | SANGER | |||
| NCI-H2405 | Growth Inhibition Assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 2.68417 μM. | SANGER | |||
| MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 2.69293 μM. | SANGER | |||
| HAL-01 | Growth Inhibition Assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 2.74249 μM. | SANGER | |||
| COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 2.76602 μM. | SANGER | |||
| HT-1080 | Growth Inhibition Assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 2.76838 μM. | SANGER | |||
| NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 2.80694 μM. | SANGER | |||
| BFTC-909 | Growth Inhibition Assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 2.88386 μM. | SANGER | |||
| LB2518-MEL | Growth Inhibition Assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 2.92298 μM. | SANGER | |||
| HC-1 | Growth Inhibition Assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 2.92852 μM. | SANGER | |||
| NCI-H661 | Growth Inhibition Assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 3.01168 μM. | SANGER | |||
| DoTc2-4510 | Growth Inhibition Assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 3.1079 μM. | SANGER | |||
| KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 3.1079 μM. | SANGER | |||
| OAW-28 | Growth Inhibition Assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 3.11075 μM. | SANGER | |||
| VM-CUB-1 | Growth Inhibition Assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 3.13715 μM. | SANGER | |||
| HCC1569 | Growth Inhibition Assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 3.16762 μM. | SANGER | |||
| MMAC-SF | Growth Inhibition Assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 3.1697 μM. | SANGER | |||
| RERF-LC-MS | Growth Inhibition Assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 3.17549 μM. | SANGER | |||
| HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 3.20817 μM. | SANGER | |||
| C-4-II | Growth Inhibition Assay | Inhibition of human C-4-II cell growth in a cell viability assay, IC50 = 3.25771 μM. | SANGER | |||
| GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 3.31731 μM. | SANGER | |||
| OVCAR-8 | Growth Inhibition Assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 3.34206 μM. | SANGER | |||
| HLE | Growth Inhibition Assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 3.34577 μM. | SANGER | |||
| CHL-1 | Growth Inhibition Assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 3.34883 μM. | SANGER | |||
| NCI-H2030 | Growth Inhibition Assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 3.37653 μM. | SANGER | |||
| ES7 | Growth Inhibition Assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 3.39911 μM. | SANGER | |||
| GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 3.41732 μM. | SANGER | |||
| NCI-H1623 | Growth Inhibition Assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 3.42053 μM. | SANGER | |||
| COLO-678 | Growth Inhibition Assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 3.44564 μM. | SANGER | |||
| Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 3.46887 μM. | SANGER | |||
| EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 3.51436 μM. | SANGER | |||
| LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 3.51627 μM. | SANGER | |||
| LC4-1 | Growth Inhibition Assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50 = 3.55663 μM. | SANGER | |||
| CTB-1 | Growth Inhibition Assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 3.56175 μM. | SANGER | |||
| ChaGo-K-1 | Growth Inhibition Assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 3.58434 μM. | SANGER | |||
| NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 3.64943 μM. | SANGER | |||
| HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 3.66857 μM. | SANGER | |||
| DV-90 | Growth Inhibition Assay | Inhibition of human DV-90 cell growth in a cell viability assay, IC50 = 3.67678 μM. | SANGER | |||
| MRK-nu-1 | Growth Inhibition Assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50 = 3.70735 μM. | SANGER | |||
| RPMI-8402 | Growth Inhibition Assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50 = 3.71196 μM. | SANGER | |||
| HCE-T | Growth Inhibition Assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 3.71981 μM. | SANGER | |||
| BPH-1 | Growth Inhibition Assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 3.8199 μM. | SANGER | |||
| D-263MG | Growth Inhibition Assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 3.84417 μM. | SANGER | |||
| U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 4.02428 μM. | SANGER | |||
| SN12C | Growth Inhibition Assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 4.04292 μM. | SANGER | |||
| KURAMOCHI | Growth Inhibition Assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50 = 4.05467 μM. | SANGER | |||
| COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 4.1346 μM. | SANGER | |||
| GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 4.17635 μM. | SANGER | |||
| NCI-H2081 | Growth Inhibition Assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50 = 4.28007 μM. | SANGER | |||
| KNS-81-FD | Growth Inhibition Assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 4.40655 μM. | SANGER | |||
| Calu-6 | Growth Inhibition Assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 4.41101 μM. | SANGER | |||
| U251 | Growth Inhibition Assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 4.44884 μM. | SANGER | |||
| KP-4 | Growth Inhibition Assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 4.49305 μM. | SANGER | |||
| HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 4.49657 μM. | SANGER | |||
| NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 4.5022 μM. | SANGER | |||
| SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 4.53506 μM. | SANGER | |||
| HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 4.54405 μM. | SANGER | |||
| NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 4.5776 μM. | SANGER | |||
| CA46 | Growth Inhibition Assay | Inhibition of human CA46 cell growth in a cell viability assay, IC50 = 4.59584 μM. | SANGER | |||
| NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 4.62915 μM. | SANGER | |||
| CESS | Growth Inhibition Assay | Inhibition of human CESS cell growth in a cell viability assay, IC50 = 4.65205 μM. | SANGER | |||
| MHH-CALL-2 | Growth Inhibition Assay | Inhibition of human MHH-CALL-2 cell growth in a cell viability assay, IC50 = 4.68861 μM. | SANGER | |||
| UM-UC-3 | Growth Inhibition Assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 4.71548 μM. | SANGER | |||
| LXF-289 | Growth Inhibition Assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 4.74443 μM. | SANGER | |||
| T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 4.76635 μM. | SANGER | |||
| TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 4.81703 μM. | SANGER | |||
| ECC4 | Growth Inhibition Assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50 = 4.83833 μM. | SANGER | |||
| CAL-33 | Growth Inhibition Assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 4.84825 μM. | SANGER | |||
| SW13 | Growth Inhibition Assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 4.87146 μM. | SANGER | |||
| 769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 4.88193 μM. | SANGER | |||
| U-2-OS | Growth Inhibition Assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 4.90779 μM. | SANGER | |||
| LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 4.92749 μM. | SANGER | |||
| NCI-H345 | Growth Inhibition Assay | Inhibition of human NCI-H345 cell growth in a cell viability assay, IC50 = 4.96365 μM. | SANGER | |||
| NCI-H1694 | Growth Inhibition Assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50 = 4.96855 μM. | SANGER | |||
| C2BBe1 | Growth Inhibition Assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 4.98155 μM. | SANGER | |||
| COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 5.06788 μM. | SANGER | |||
| LC-1F | Growth Inhibition Assay | Inhibition of human LC-1F cell growth in a cell viability assay, IC50 = 5.0921 μM. | SANGER | |||
| A2058 | Growth Inhibition Assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 5.26272 μM. | SANGER | |||
| MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 5.32484 μM. | SANGER | |||
| DU-4475 | Growth Inhibition Assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 5.36197 μM. | SANGER | |||
| SNU-C2B | Growth Inhibition Assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50 = 5.44771 μM. | SANGER | |||
| TUR | Growth Inhibition Assay | Inhibition of human TUR cell growth in a cell viability assay, IC50 = 5.51595 μM. | SANGER | |||
| Daudi | Growth Inhibition Assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50 = 5.51694 μM. | SANGER | |||
| IMR-5 | Growth Inhibition Assay | Inhibition of human IMR-5 cell growth in a cell viability assay, IC50 = 5.6021 μM. | SANGER | |||
| IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 5.63247 μM. | SANGER | |||
| NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 5.64209 μM. | SANGER | |||
| LOUCY | Growth Inhibition Assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50 = 5.66174 μM. | SANGER | |||
| NCI-H1963 | Growth Inhibition Assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50 = 5.66692 μM. | SANGER | |||
| KMOE-2 | Growth Inhibition Assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 5.7626 μM. | SANGER | |||
| HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 5.78117 μM. | SANGER | |||
| SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 5.81309 μM. | SANGER | |||
| GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 5.99711 μM. | SANGER | |||
| BHT-101 | Growth Inhibition Assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 6.0215 μM. | SANGER | |||
| MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 6.10704 μM. | SANGER | |||
| D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 6.17633 μM. | SANGER | |||
| HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 6.20084 μM. | SANGER | |||
| IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 6.23432 μM. | SANGER | |||
| LP-1 | Growth Inhibition Assay | Inhibition of human LP-1 cell growth in a cell viability assay, IC50 = 6.27356 μM. | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 6.29707 μM. | SANGER | |||
| M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 6.58861 μM. | SANGER | |||
| HT-1376 | Growth Inhibition Assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 6.62249 μM. | SANGER | |||
| RPMI-7951 | Growth Inhibition Assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 6.64003 μM. | SANGER | |||
| NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 6.64282 μM. | SANGER | |||
| Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 6.6908 μM. | SANGER | |||
| NCI-H2227 | Growth Inhibition Assay | Inhibition of human NCI-H2227 cell growth in a cell viability assay, IC50 = 6.72244 μM. | SANGER | |||
| L-540 | Growth Inhibition Assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50 = 6.97353 μM. | SANGER | |||
| NALM-6 | Growth Inhibition Assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50 = 7.12163 μM. | SANGER | |||
| HCC1143 | Growth Inhibition Assay | Inhibition of human HCC1143 cell growth in a cell viability assay, IC50 = 7.1789 μM. | SANGER | |||
| CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 7.30834 μM. | SANGER | |||
| CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 7.37047 μM. | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 7.54014 μM. | SANGER | |||
| NCI-H1573 | Growth Inhibition Assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50 = 7.56522 μM. | SANGER | |||
| 697 | Growth Inhibition Assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 7.58666 μM. | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 7.85618 μM. | SANGER | |||
| HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 8.02849 μM. | SANGER | |||
| KARPAS-422 | Growth Inhibition Assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50 = 8.03517 μM. | SANGER | |||
| BT-20 | Growth Inhibition Assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 8.42844 μM. | SANGER | |||
| MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 8.54339 μM. | SANGER | |||
| DMS-114 | Growth Inhibition Assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50 = 8.66749 μM. | SANGER | |||
| EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 8.66955 μM. | SANGER | |||
| NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 8.86699 μM. | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 9.16845 μM. | SANGER | |||
| ME-180 | Growth Inhibition Assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 9.25521 μM. | SANGER | |||
| PFSK-1 | Growth Inhibition Assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 9.38893 μM. | SANGER | |||
| NCI-H1522 | Growth Inhibition Assay | Inhibition of human NCI-H1522 cell growth in a cell viability assay, IC50 = 9.63917 μM. | SANGER | |||
| SR | Growth Inhibition Assay | Inhibition of human SR cell growth in a cell viability assay, IC50 = 9.8234 μM. | SANGER | |||
| LU-165 | Growth Inhibition Assay | Inhibition of human LU-165 cell growth in a cell viability assay, IC50 = 9.835 μM. | SANGER | |||
| EB2 | Growth Inhibition Assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50 = 9.8583 μM. | SANGER | |||
| C3A | Growth Inhibition Assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 9.87709 μM. | SANGER | |||
| NCI-H1793 | Growth Inhibition Assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 9.90289 μM. | SANGER | |||
| NCI-H28 | Growth Inhibition Assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 10.1407 μM. | SANGER | |||
| UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 10.4166 μM. | SANGER | |||
| MDA-MB-134-VI | Growth Inhibition Assay | Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50 = 10.6056 μM. | SANGER | |||
| IST-SL2 | Growth Inhibition Assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50 = 10.6583 μM. | SANGER | |||
| CGTH-W-1 | Growth Inhibition Assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 10.7825 μM. | SANGER | |||
| C-33-A | Growth Inhibition Assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 10.7975 μM. | SANGER | |||
| Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 10.8458 μM. | SANGER | |||
| MZ7-mel | Growth Inhibition Assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 11.0898 μM. | SANGER | |||
| KP-N-YS | Growth Inhibition Assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 11.4914 μM. | SANGER | |||
| LB373-MEL-D | Growth Inhibition Assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50 = 11.8696 μM. | SANGER | |||
| NCI-H520 | Growth Inhibition Assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 11.9407 μM. | SANGER | |||
| CAL-148 | Growth Inhibition Assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50 = 12.0776 μM. | SANGER | |||
| KYSE-70 | Growth Inhibition Assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 12.1046 μM. | SANGER | |||
| OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 12.1331 μM. | SANGER | |||
| SBC-1 | Growth Inhibition Assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 12.1884 μM. | SANGER | |||
| NCI-H1993 | Growth Inhibition Assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 12.2994 μM. | SANGER | |||
| Calu-1 | Growth Inhibition Assay | Inhibition of human Calu-1 cell growth in a cell viability assay, IC50 = 12.3415 μM. | SANGER | |||
| WSU-NHL | Growth Inhibition Assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50 = 12.3788 μM. | SANGER | |||
| J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 12.4848 μM. | SANGER | |||
| PA-1 | Growth Inhibition Assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 12.5451 μM. | SANGER | |||
| IM-9 | Growth Inhibition Assay | Inhibition of human IM-9 cell growth in a cell viability assay, IC50 = 12.7138 μM. | SANGER | |||
| KM-H2 | Growth Inhibition Assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 12.7654 μM. | SANGER | |||
| U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 13.0415 μM. | SANGER | |||
| HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 13.4808 μM. | SANGER | |||
| DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 13.7045 μM. | SANGER | |||
| BOKU | Growth Inhibition Assay | Inhibition of human BOKU cell growth in a cell viability assay, IC50 = 13.8328 μM. | SANGER | |||
| HCC38 | Growth Inhibition Assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 13.8335 μM. | SANGER | |||
| MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 13.9601 μM. | SANGER | |||
| FTC-133 | Growth Inhibition Assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 14.139 μM. | SANGER | |||
| MC-CAR | Growth Inhibition Assay | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50 = 14.5038 μM. | SANGER | |||
| THP-1 | Growth Inhibition Assay | Inhibition of human THP-1 cell growth in a cell viability assay, IC50 = 14.614 μM. | SANGER | |||
| HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 14.7066 μM. | SANGER | |||
| NCI-H1155 | Growth Inhibition Assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 14.7657 μM. | SANGER | |||
| D-392MG | Growth Inhibition Assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 15.198 μM. | SANGER | |||
| HT-1197 | Growth Inhibition Assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 15.2627 μM. | SANGER | |||
| T98G | Growth Inhibition Assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 16.2469 μM. | SANGER | |||
| BC-3 | Growth Inhibition Assay | Inhibition of human BC-3 cell growth in a cell viability assay, IC50 = 16.3723 μM. | SANGER | |||
| DMS-53 | Growth Inhibition Assay | Inhibition of human DMS-53 cell growth in a cell viability assay, IC50 = 16.4241 μM. | SANGER | |||
| PC-14 | Growth Inhibition Assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 16.496 μM. | SANGER | |||
| NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 16.5926 μM. | SANGER | |||
| ARH-77 | Growth Inhibition Assay | Inhibition of human ARH-77 cell growth in a cell viability assay, IC50 = 16.9307 μM. | SANGER | |||
| NCI-H1436 | Growth Inhibition Assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50 = 17.2361 μM. | SANGER | |||
| RCM-1 | Growth Inhibition Assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 17.9934 μM. | SANGER | |||
| CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 18.1382 μM. | SANGER | |||
| JiyoyeP-2003 | Growth Inhibition Assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50 = 18.3276 μM. | SANGER | |||
| AsPC-1 | Growth Inhibition Assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 18.8638 μM. | SANGER | |||
| OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 19.0924 μM. | SANGER | |||
| RO82-W-1 | Growth Inhibition Assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 19.2558 μM. | SANGER | |||
| NCI-H209 | Growth Inhibition Assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 19.2741 μM. | SANGER | |||
| RPMI-6666 | Growth Inhibition Assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50 = 19.3018 μM. | SANGER | |||
| P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 19.6604 μM. | SANGER | |||
| SW1990 | Growth Inhibition Assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 19.7833 μM. | SANGER | |||
| A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 20.0041 μM. | SANGER | |||
| Calu-3 | Growth Inhibition Assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 20.0694 μM. | SANGER | |||
| SW1463 | Growth Inhibition Assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 20.0705 μM. | SANGER | |||
| YT | Growth Inhibition Assay | Inhibition of human YT cell growth in a cell viability assay, IC50 = 20.687 μM. | SANGER | |||
| MDA-MB-175-VII | Growth Inhibition Assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 20.7094 μM. | SANGER | |||
| NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 20.8286 μM. | SANGER | |||
| COLO-792 | Growth Inhibition Assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 20.8786 μM. | SANGER | |||
| NCI-H748 | Growth Inhibition Assay | Inhibition of human NCI-H748 cell growth in a cell viability assay, IC50 = 20.9574 μM. | SANGER | |||
| SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 21.0448 μM. | SANGER | |||
| REH | Growth Inhibition Assay | Inhibition of human REH cell growth in a cell viability assay, IC50 = 21.0864 μM. | SANGER | |||
| HEC-1 | Growth Inhibition Assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 21.8654 μM. | SANGER | |||
| no-10 | Growth Inhibition Assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 22.6912 μM. | SANGER | |||
| EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 23.3021 μM. | SANGER | |||
| LN-405 | Growth Inhibition Assay | Inhibition of human LN-405 cell growth in a cell viability assay, IC50 = 23.4328 μM. | SANGER | |||
| RVH-421 | Growth Inhibition Assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 23.6492 μM. | SANGER | |||
| CAMA-1 | Growth Inhibition Assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 24.0797 μM. | SANGER | |||
| MDA-MB-453 | Growth Inhibition Assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 24.4188 μM. | SANGER | |||
| EFO-27 | Growth Inhibition Assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 24.4381 μM. | SANGER | |||
| LU-139 | Growth Inhibition Assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 24.4583 μM. | SANGER | |||
| YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 25.4403 μM. | SANGER | |||
| CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 25.4533 μM. | SANGER | |||
| DJM-1 | Growth Inhibition Assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 26.0811 μM. | SANGER | |||
| SNU-475 | Growth Inhibition Assay | Inhibition of human SNU-475 cell growth in a cell viability assay, IC50 = 26.345 μM. | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 26.4762 μM. | SANGER | |||
| HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 26.7959 μM. | SANGER | |||
| EFM-19 | Growth Inhibition Assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 26.8204 μM. | SANGER | |||
| HT | Growth Inhibition Assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 27.169 μM. | SANGER | |||
| NCI-H64 | Growth Inhibition Assay | Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50 = 28.2381 μM. | SANGER | |||
| JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 28.3241 μM. | SANGER | |||
| CAL-27 | Growth Inhibition Assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 28.4822 μM. | SANGER | |||
| HSC-4 | Growth Inhibition Assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50 = 28.7306 μM. | SANGER | |||
| HCC1599 | Growth Inhibition Assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50 = 29.235 μM. | SANGER | |||
| TE-5 | Growth Inhibition Assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 30.5378 μM. | SANGER | |||
| IPC-298 | Growth Inhibition Assay | Inhibition of human IPC-298 cell growth in a cell viability assay, IC50 = 30.9652 μM. | SANGER | |||
| EHEB | Growth Inhibition Assay | Inhibition of human EHEB cell growth in a cell viability assay, IC50 = 31.1889 μM. | SANGER | |||
| NCI-H322M | Growth Inhibition Assay | Inhibition of human NCI-H322M cell growth in a cell viability assay, IC50 = 33.5237 μM. | SANGER | |||
| A253 | Growth Inhibition Assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 34.0349 μM. | SANGER | |||
| NCI-H596 | Growth Inhibition Assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50 = 34.8541 μM. | SANGER | |||
| MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 35.9922 μM. | SANGER | |||
| C32 | Growth Inhibition Assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 37.6212 μM. | SANGER | |||
| SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 37.8733 μM. | SANGER | |||
| COR-L279 | Growth Inhibition Assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50 = 37.9052 μM. | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 38.4987 μM. | SANGER | |||
| RT4 | Growth Inhibition Assay | Inhibition of human RT4 cell growth in a cell viability assay, IC50 = 39.105 μM. | SANGER | |||
| MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 39.1717 μM. | SANGER | |||
| KYSE-520 | Growth Inhibition Assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 39.3112 μM. | SANGER | |||
| NCI-H2196 | Growth Inhibition Assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50 = 40.0071 μM. | SANGER | |||
| MKN1 | Growth Inhibition Assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 40.2345 μM. | SANGER | |||
| HN | Growth Inhibition Assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 40.5211 μM. | SANGER | |||
| MFE-280 | Growth Inhibition Assay | Inhibition of human MFE-280 cell growth in a cell viability assay, IC50 = 41.3794 μM. | SANGER | |||
| 647-V | Growth Inhibition Assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 41.8832 μM. | SANGER | |||
| PF-382 | Growth Inhibition Assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50 = 42.0242 μM. | SANGER | |||
| IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 42.3247 μM. | SANGER | |||
| MKN7 | Growth Inhibition Assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 42.4977 μM. | SANGER | |||
| CP50-MEL-B | Growth Inhibition Assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 42.6901 μM. | SANGER | |||
| K052 | Growth Inhibition Assay | Inhibition of human K052 cell growth in a cell viability assay, IC50 = 43.0698 μM. | SANGER | |||
| 23132-87 | Growth Inhibition Assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50 = 43.5286 μM. | SANGER | |||
| GAK | Growth Inhibition Assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 44.127 μM. | SANGER | |||
| Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 45.5878 μM. | SANGER | |||
| RMG-I | Growth Inhibition Assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 45.7372 μM. | SANGER | |||
| BE-13 | Growth Inhibition Assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 45.9392 μM. | SANGER | |||
| SW684 | Growth Inhibition Assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50 = 47.4969 μM. | SANGER | |||
| Clicca per visualizzare più dati sperimentali sulle linee cellulari | ||||||
Informazioni chimiche, conservazione e stabilità
| Peso molecolare | 461.49 | Formula | C23H24FN9O |
Conservazione (Dalla data di ricezione) | |
|---|---|---|---|---|---|
| N. CAS | 1001350-96-4 | Scarica SDF | Conservazione delle soluzioni stock |
|
|
| Sinonimi | N/A | Smiles | CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F | ||
Solubilità
|
In vitro |
DMSO
: 92 mg/mL
(199.35 mM)
Ethanol : 92 mg/mL Water : Insoluble |
Calcolatore di Molarità
Calcolatore di Diluizione
Calcolatore del Peso Molecolare
|
In vivo |
|||||
Calcolatore di formulazione in vivo (Soluzione chiara)
Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante lesperimento)
mg/kg
g
μL
Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non cè una formulazione in vivo nella sezione Solubilità.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Risultati del calcolo:
Concentrazione di lavoro: mg/ml;
Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.
Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nellaggiunta precedente, sia una soluzione limpida prima di procedere allaggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno dacqua calda possono essere utilizzati per facilitare la dissoluzione.
Meccanismo dazione
| Caratteristiche |
Muti-inhibitor of the IGR-1R/IR family.
|
|---|---|
| Targets/IC50/Ki |
Insulin Receptor
(Cell-free assay) 1.7 nM
IGF-1R
(Cell-free assay) 1.8 nM
TrkB
(Cell-free assay) 4.1 nM
Met
(Cell-free assay) 5.6 nM
TrkA
(Cell-free assay) 7.4 nM
Aurora A
(Cell-free assay) 9 nM
Aurora B
(Cell-free assay) 25 nM
RON
(Cell-free assay) 44 nM
FLT3
(Cell-free assay) 170 nM
|
| In vitro |
BMS-754807 inibisce efficacemente la crescita di un'ampia gamma di linee cellulari tumorali umane di diverse origini istologiche, incluse mesenchimali (sarcoma di Ewing, rabdomiosarcoma, neuroblastoma e liposarcoma), epiteliali (seno, polmone, pancreas, colon e gastriche) ed ematopoietiche (mieloma multiplo e leucemia), con valori di IC50 che vanno da 5 nM a 365 nM per le linee cellulari più sensibili. Questo composto inibisce la proliferazione delle cellule IGF-1R-Sal e delle cellule RH41 con IC50 di 7 nM e 5 nM. Inibisce la fosforilazione di IGF-1R nelle cellule IGF-1R-Sal, Rh41 e Geo con IC50 di 13 nM, 6 nM e 21 nM. Questo composto chimico inibisce la fosforilazione di Akt nelle cellule IGF-1R-Sal, Rh41 e Geo con IC50 di 22 nM, 13 nM e 16 nM. Induce una maggiore apoptosi nelle cellule Rh41 entro 24 ore, come indicato da un aumento del picco sub-G1 (23,1%), rispetto al controllo (2,4%). Questo composto inibisce la fosforilazione di IGF-1R (IC50 = 13nM) e i bersagli a valle Akt (IC50 = 22nM) e MAPK (IC50 = 13nM) nella linea cellulare IGF-Sal con IC50 coerente con l'IC50 antiproliferativa (7 nM) in questa linea cellulare. La struttura cristallina di questo composto cocristallizzato con il dominio chinasi di IGF-1R mostra la triade di legami idrogeno donatore/accettore/donatore con Met1052 e Glu1050 all'interno della regione a cerniera della chinasi. Mostra un valore mediano di EC50 di 0,62 μM contro 23 linee cellulari nel programma di test preclinici pediatrici (PPTP). |
| Saggio chinasico |
Saggi di inibizione della chinasi
|
|
Lo screening primario per BMS-754807 è un saggio chinasico in vitro che utilizza l'enzima ricombinante del recettore IGF-1 umano in saggi biochimici con il peptide sintetico KKSRGDYMTMQIG come substrato fosfoaccettore. Il profilo di selettività viene valutato contro diverse enzimi ricombinanti che vengono generati presso BMS o acquistati esternamente. I saggi enzimatici vengono eseguiti in piastre a 384 pozzetti con fondo a U utilizzando un volume di reazione di 30 μL in tampone di saggio (100 mM Hepes pH 7.4, 10 mM MgCl2, 0,015% Brij35 e 4 mM DTT). Le reazioni di 60 minuti sono avviate combinando ATP (concentrazione equivalente a Km ATP), 1,5 μM di substrato peptidico marcato, enzima e questo composto. Le reazioni vengono terminate con EDTA. Le miscele di reazione vengono analizzate sul Caliper LabChip 3000 mediante separazione elettroforetica del substrato fluorescente e del prodotto fosforilato. I dati di inibizione vengono calcolati confrontandoli con le reazioni di controllo senza enzima per il 100% di inibizione e le reazioni con solo veicolo per lo 0% di inibizione. I composti vengono sciolti in DMSO, stock 10mM e valutati a undici concentrazioni. I valori di IC50 vengono derivati mediante analisi di regressione non lineare delle curve dose-risposta.
|
|
| In vivo |
BMS-754807 (12,5 mg/kg, per via orale) inibisce la fosforilazione di IGF-1R nel tumore e nel siero in topi nudi portatori di tumore IGF-1R-Sal. Questo composto inibisce la crescita tumorale in un gruppo selezionato di modelli di xenotrapianto tumorale epiteliale (IGF-1R-Sal, GEO e Colo205), ematopoietico (JJN3) e mesenchimale (RD1 e Rh41) con TGI che varia dal 53% al 115%. Esso (6,25 mg/kg) raggiunge un'inibizione completa della crescita tumorale nel modello di topo transgenico con tumore IGF-Sal derivato, con un'inibizione correlata di pIGF-1R e pAKT. Il legame proteico per questo composto chimico varia dal 98,5% nel plasma di topo al 95,9% nel plasma umano. Esso provoca una clearance di 113 (mL/min)/kg, 20 (mL/min)/kg, 3,5 (mL/min)/kg e 41 (mL/min)/kg. Questo composto (25 mg/kg) inibisce significativamente il tumore nei modelli murini di xenotrapianti KT-5 (Wilms), KT-14 (rabdoide), Rh28 (rabdomiosarcoma) e OS-1. |
Riferimenti |
|
Applicazioni
| Metodi | Biomarcatori | Immagini | PMID |
|---|---|---|---|
| Growth inhibition assay | Cell viability |
|
30754629 |
| Western blot | p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK |
|
26136493 |
Informazioni sullo studio clinico
(dati da https://clinicaltrials.gov, aggiornato il 2024-05-22)
| Numero NCT | Reclutamento | Condizioni | Sponsor/Collaboratori | Data di inizio | Fasi |
|---|---|---|---|---|---|
| NCT01525823 | Completed | Healthy Volunteers |
Bristol-Myers Squibb |
February 2012 | Phase 1 |
| NCT00908024 | Terminated | Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis |
Bristol-Myers Squibb |
October 2009 | Phase 1|Phase 2 |
| NCT00898716 | Completed | Neoplasms |
Bristol-Myers Squibb |
September 2009 | Phase 1 |
| NCT00788333 | Completed | Breast Cancer |
Bristol-Myers Squibb |
July 2009 | Phase 1|Phase 2 |
Supporto tecnico
Istruzioni per la manipolazione
Tel: +1-832-582-8158 Ext:3
Per qualsiasi altra domanda, si prega di lasciare un messaggio.
I prodotti sono solo per uso di ricerca. Non per uso umano. Non vendiamo a pazienti.
©Copyright 2013 Selleck Chemicals. Tutti i diritti riservati.